Baudet E M, Puel V, McBride J T, Grimaud J P, Roques F, Clerc F, Roques X, Laborde N
Department of Cardiovascular and Pediatric Cardiac Surgery, Haut-Leveque Heart Hospital, Bordeaux, France.
J Thorac Cardiovasc Surg. 1995 May;109(5):858-70. doi: 10.1016/S0022-5223(95)70309-8.
To assess with truly long follow-up the long-term results of valve replacement with the St. Jude Medical prosthesis (St. Jude Medical, Inc., St. Paul, Minn.), we reviewed the case histories of the first 1112 patients undergoing 1244 valve replacements with this valve between June 12, 1978, and June 12, 1987: 690 male (62%) and 422 female patients, mean age 56 years. A total of 773 patients (69%) had the aortic valve replaced, 207 (19%) the mitral valve, and 132 (12%) the aortic and mitral valves. There were 42 hospital deaths (3.8%). Follow-up was 97.5% complete (8988 patient-years). There were 213 late deaths. Ninety-one (43%) were considered valve-related: sudden death, n = 27; anticoagulant-related hemorrhage, n = 22; thromboembolism, n = 19; prosthetic valve endocarditis, n = 13; valve thrombosis, n = 9; and noninfectious perivalvular leak, n = 1. Overall actuarial survival, including hospital mortality, was 68% +/- 6% (95% confidence limits) 14 years after the operation. Linearized rates of late valve-related events were as follows: thromboembolism, 1.09% per patient-year; anticoagulant-related hemorrhage, 0.94% per patient-year; prosthetic valve endocarditis, 0.32% per patient-year; valve thrombosis, 0.33% per patient-year; and perivalvular leak, 0.19% per patient-year. Actuarial freedom, at 14 years, from thromboembolism was 89% +/- 3%, anticoagulant-related hemorrhage 83% +/- 8%, valve thrombosis 97% +/- 1%, and reoperation 95% +/- 3%. Actuarial freedom from all valve-related deaths and valve-related morbidity and mortality, at 14 years, was 84% +/- 6% and 61% +/- 8%, respectively. We conclude that, because of its low thrombogenicity, low incidence of valve-related events, and low valve-related mortality, the St. Jude Medical valve is one of the best performing mechanical prosthesis currently available. Nevertheless, the late valve-related complications and deaths illustrate that the quest for a "perfect" prosthesis remains unfulfilled.
为了通过真正长期的随访来评估圣犹达医疗公司(位于明尼苏达州圣保罗市)生产的人工心脏瓣膜置换术的长期效果,我们回顾了1978年6月12日至1987年6月12日期间接受该瓣膜进行1244次瓣膜置换的前1112例患者的病历:男性690例(62%),女性422例,平均年龄56岁。共有773例患者(69%)接受了主动脉瓣置换,207例(19%)接受了二尖瓣置换,132例(12%)接受了主动脉瓣和二尖瓣置换。有42例医院死亡(3.8%)。随访完成率为97.5%(8988患者年)。有213例晚期死亡。其中91例(43%)被认为与瓣膜相关:猝死27例;抗凝相关出血22例;血栓栓塞19例;人工瓣膜心内膜炎13例;瓣膜血栓形成9例;非感染性瓣周漏1例。包括医院死亡率在内的总体精算生存率在术后14年为68%±6%(95%置信区间)。晚期瓣膜相关事件的线性化发生率如下:血栓栓塞,每年每例患者1.09%;抗凝相关出血,每年每例患者0.94%;人工瓣膜心内膜炎,每年每例患者0.32%;瓣膜血栓形成,每年每例患者0.33%;瓣周漏,每年每例患者0.19%。14年时血栓栓塞的精算无事件生存率为89%±3%,抗凝相关出血为83%±8%,瓣膜血栓形成为97%±1%,再次手术为95%±3%。14年时所有瓣膜相关死亡以及瓣膜相关发病率和死亡率的精算无事件生存率分别为84%±6%和61%±8%。我们得出结论,由于其低血栓形成性、低瓣膜相关事件发生率以及低瓣膜相关死亡率,圣犹达医疗瓣膜是目前性能最佳的机械人工瓣膜之一。然而,晚期瓣膜相关并发症和死亡表明对“完美”人工瓣膜的追求仍未实现。